[Ac-225]-PSMA-62

N/A

Report date: 2025/11/20 16:00:35

NME

Base Information

Drug Name[Ac-225]-PSMA-62

Drug Alias Name[(A)c-225]-PSMA-62[Ac-225]-PSMA-62225Ac-PSMA-62

ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionIonising radiation emitters

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPoint Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company

Inactive CompaniesN/A

Active IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A